These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 34760642)

  • 21. Justice in jeopardy: a qualitative study of institutional ethics committees in New Delhi.
    Kandhari R
    Indian J Med Ethics; 2013; 10(3):176-83. PubMed ID: 23912731
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A review of clinical trials registered in India from 2008 to 2022 to describe the first-in-human trials.
    Sabu ST; Venkatraman S; Cherian JJ; Das S; Pahuja M; Adhikari T; Mukherjee S; Chatterjee NS; Kshirsagar NA
    Perspect Clin Res; 2024; 15(1):18-23. PubMed ID: 38282636
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A critical appraisal of clinical trials conducted and subsequent drug approvals in India and South Africa.
    Limaye D; Langer JM; Rühling T; Fortwengel G
    BMJ Open; 2015 Aug; 5(8):e007304. PubMed ID: 26324720
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An audit of the approval letters issued by Drugs Controller General of India to Ethics Committees in India.
    Bhide SS; Katkar JV; Maurya M; Gogtay NJ; Thatte UM
    Perspect Clin Res; 2016; 7(4):165-167. PubMed ID: 27843791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Establishing institutional ethics committees: challenges and solutions - a review of the literature.
    Kuyare MS; Taur SR; Thatte UM
    Indian J Med Ethics; 2014; 11(3):181-5. PubMed ID: 25160969
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evolving role of ethics committees in India.
    Cash RA
    Indian J Med Ethics; 2013; 10(3):206. PubMed ID: 23912739
    [No Abstract]   [Full Text] [Related]  

  • 27. Experience of an academic institute in importing a novel preclinical drug into India.
    Kumar MP; Medhi B
    Indian J Pharmacol; 2017; 49(4):322-324. PubMed ID: 29326494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Surfactant-assisted fabrication of 3D Prussian blue-reduced graphene oxide hydrogel as a self-propelling motor for water treatment.
    Hao J; Yang W; Zhang Z; Tang J
    Nanoscale; 2015 Jun; 7(23):10498-503. PubMed ID: 26009257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IRB review of adverse events in investigational drug studies.
    Prentice ED; Gordon B
    IRB; 1997; 19(6):1-4. PubMed ID: 11656910
    [No Abstract]   [Full Text] [Related]  

  • 30. Forest ecosystem services contribution to food security of vulnerable group: a case study from India.
    Balasubramanian M
    Environ Monit Assess; 2021 Nov; 193(12):792. PubMed ID: 34762161
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The trend of forest ecosystem services assessment in eastern India: a review for future research insights.
    Das A; Mallick PH
    Environ Monit Assess; 2023 Apr; 195(5):615. PubMed ID: 37100992
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Availability of Investigational Medicines Through the US Food and Drug Administration's Expanded Access and Compassionate Use Programs.
    Puthumana J; Miller JE; Kim J; Ross JS
    JAMA Netw Open; 2018 Jun; 1(2):e180283. PubMed ID: 30646072
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Examining the effects of green revolution led agricultural expansion on net ecosystem service values in India using multiple valuation approaches.
    Sannigrahi S; Pilla F; Zhang Q; Chakraborti S; Wang Y; Basu B; Basu AS; Joshi PK; Keesstra S; Roy PS; Sutton PC; Bhatt S; Rahmat S; Jha S; Singh LK
    J Environ Manage; 2021 Jan; 277():111381. PubMed ID: 33011421
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Charging for investigational drugs under an investigational new drug application. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Aug; 74(155):40871-900. PubMed ID: 19691172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Provision of investigational drug after clinical research: review of literature, national and international guidelines.
    Dainesi SM; Goldbaum M
    Rev Assoc Med Bras (1992); 2011; 57(6):710-6. PubMed ID: 22249554
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer, access to investigational drugs, and patient rights in the U.S.A. and India.
    Sheehan HE
    Indian J Med Ethics; 2008; 5(4):170-2; discussion 173. PubMed ID: 18988376
    [No Abstract]   [Full Text] [Related]  

  • 38. [Recording and reporting adverse reactions in clinical trials. New legal provisions according to the 12th Law Amending the German Drug Law (AMG) and the Ordinance on GCP (GCP-V)].
    Eckhardt K; Cremer-Schaeffer P; König J; Paeschke N
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Feb; 48(2):173-80. PubMed ID: 15726458
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FDA's new rule on treatment use and sale of investigational new drugs.
    Levine RJ
    IRB; 1987; 9(4):1-4. PubMed ID: 11649946
    [No Abstract]   [Full Text] [Related]  

  • 40. Expanding Patient Access to Investigational Drugs: Single Patient Investigational New Drug and the "Right to Try".
    Van Norman GA
    JACC Basic Transl Sci; 2018 Apr; 3(2):280-293. PubMed ID: 30062214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.